Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472861 | 0.80 | DHFR (0.49) | DHFRPIN1HPGDSADORA2AADORA1 | |
| SCHEMBL29430388 | 0.80 | DHFR (0.49) | DHFRPIN1HPGDSADORA2AADORA1 | |
| SCHEMBL4468439 | 0.78 | DHFR (0.57) | DHFRHPGDSADORA2AADORA1FGFR1 | |
| SCHEMBL29430444 | 0.78 | DHFR (0.57) | DHFRHPGDSADORA2AADORA1FGFR1 | |
| SCHEMBL1919495 | 0.78 | HPGDS (0.52) | PIN1HPGDSBRD4ADORA2AADORA1 | |
| SCHEMBL27613072 | 0.74 | DHFR (0.59) | DHFRADORA2AADORA1FGFR1 | |
| SCHEMBL4904620 | 0.73 | ALDH1A1 (0.46) | PIN1HPGDSBRD4ADORA2AADORA1 | |
| SCHEMBL7256620 | 0.72 | BRD4 (0.39) | PIN1HPGDSBRD4ADORA2AADORA1 | |
| SCHEMBL30792106 | 0.72 | MAP4K4 (0.44) | PIN1HPGDSBRD4ADORA2AADORA1 | |
| SCHEMBL4431582 | 0.71 | BRD4 (0.48) | PIN1HPGDSBRD4LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-9181188-B2 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120136157-A1 | ARYL UREAS AS KINASE INHIBITORS | DUMAS JACQUES (US) | 2012-05-31 | — | — | US | disclosed |
| EP-1580188-B9 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-1478358-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1467736-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030216396-A1 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | BAYER CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | BAYER CORPORATION (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003068228-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068229-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003059354-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003040141-A1 | OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003040141-A1 | OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | DHFR 2323/4885PIN1 827/4885HPGDS 193/4885 |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | DHFR 2323/4885PIN1 827/4885HPGDS 193/4885 |
| US-20030216396-A1 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | MAP2K2, MAP2K7, MAPK1 | DHFR 1878/4885PIN1 527/4885HPGDS 588/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | DHFR 2323/4885PIN1 827/4885HPGDS 193/4885 |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | DHFR 2214/4885PIN1 560/4885HPGDS 196/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | DHFR 1591/4885PIN1 720/4885HPGDS 269/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | DHFR 2323/4885PIN1 827/4885HPGDS 193/4885 |
| US-20120136157-A1 | ARYL UREAS AS KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K6 | DHFR 2214/4885PIN1 560/4885HPGDS 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.